The relationship between sleep quality and medical comorbidities of psoriasis and psoriatic arthritis is poorly understood.
Objective
To evaluate the association of sleep disturbance and medical comorbidities in patients with psoriasis and psoriatic arthritis compared with healthy volunteers.
Methods
This cross-sectional study compared patients with psoriasis, patients with psoriatic arthritis, and control participants. The Pittsburgh Sleep Quality Inventory (PSQI) and the Global Fatigue Scale were used to measure sleep disturbance and fatigue.
Results
The psoriatic arthritis, psoriasis, and control groups had elevated mean PSQI scores indicating poor sleep quality; the psoriatic arthritis group had the statistically highest mean score. Psoriatic arthritis patients had higher mean body mass index and a higher prevalence of diabetes, restless leg syndrome, and insomnia.
Conclusions
Poor sleep quality and medical comorbidities were prevalent in patients with psoriasis and psoriatic arthritis but are highest in patients with psoriatic arthritis. The link between sleep disorder, psoriatic disease, and medical comorbidities deserves more study.
LeonardD.G., O'DuffyJ.D., RogersR.S.Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc.1978; 53: 511–8.
4.
ShbeebM., UramotoK.M., GibsonL.E., O'FallonW.M., GabrielS.E.The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol.2000; 27: 1247–50.
5.
TaylorS.C., KellyA.P., DupreeN.E., KimballA.B., LawrenceR.C.Health disparities in arthritis and musculoskeletal and skin diseases—the dermatology session: National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, December 15–16, 2000. J Am Acad Dermatol.2002; 47: 770–3.
6.
KooJ.Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin.1996; 14: 485–96.
7.
KruegerG., KooJ., LebwohlM., MenterA., SternR.S., RolstadT.The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol.2001; 137: 280–4.
8.
Callis DuffinK., WongB., HornE.J., KruegerG.G.Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. J Am Acad Dermatol.2009; 60: 604–8.
9.
NaldiL., ChatenoudL., LinderD.Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol.2005; 125: 61–7.
10.
ChristophersE.Comorbidities in psoriasis. Clin Dermatol.2007; 25: 529–34.
11.
HerronM.D., HinckleyM., HoffmanM.S., PapenfussJ., HansenC.B., CallisK.P.Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol.2005; 141: 1527–34.
12.
CohenA.D., SherfM., VidavskyL., VardyD.A., ShapiroJ., MeyerovitchJ.Association between psoriasis and the metabolic syndrome: a cross-sectional study. Dermatology.2008; 216: 152–5.
13.
NeimannA.L., ShinD.B., WangX., MargolisD.J., TroxelA.B., GelfandJ.M.Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol.2006; 55: 829–35.
14.
SommerD.M., JenischS., SuchanM., ChristophersE., WeichenthalM.Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res.2006; 298: 321–8.
15.
GelfandJ.M., NeimannA.L., ShinD.B., WangX., MargolisD.J., TroxelA.B.Risk of myocardial infarction in patients with psoriasis. JAMA.2006; 296: 1735–41.
16.
Lopez-JimenezF., SomersV.K.Stress measures linking sleep apnea, hypertension and diabetes—AHI vs arousals vs hypoxemia. Sleep.2006; 29: 743–4.
17.
Lopez-JimenezF., Sert KuniyoshiF.H., GamiA., SomersV.K.Obstructive sleep apnea: implications for cardiac and vascular disease. Chest.2008; 133: 793–804.
18.
KonoM., TatsumiK., SaibaraT.Obstructive sleep apnea syndrome is associated with some components of metabolic syndrome. Chest.2007; 131: 1387–92.
19.
BuscemiD., KumarA., NugentR., NugentK.Short sleep times predict obesity in internal medicine clinic patients. J Clin Sleep Med.2007; 3: 681–8.
20.
GangwischJ.E., HeymsfieldS.B., Boden-AlbalaB.Sleep duration as a risk factor for diabetes incidence in a large U.S. sample. Sleep.2007; 30: 1667–73.
21.
KnutsonK.L.Impact of sleep and sleep loss on glucose homeostasis and appetite regulation. Sleep Med Clin.2007; 2: 187–97.
22.
KnutsonK.L., Van CauterE.Associations between sleep loss and increased risk of obesity and diabetes. Ann N Y Acad Sci.2008; 1129: 287–304.
23.
SinghM., DrakeC.L., RoehrsT., HudgelD.W., RothT.The association between obesity and short sleep duration: a population-based study. J Clin Sleep Med.2005; 1: 357–63.
24.
AyasN.T., WhiteD.P., MansonJ.E.A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med.2003; 163: 205–9.
25.
MeerloP., SgoifoA., SucheckiD.Restricted and disrupted sleep: effects on autonomic function, neuroendocrine stress systems and stress responsivity. Sleep Med Rev.2008; 12: 197–210.
26.
YosipovitchG., GoonA., WeeJ., ChanY.H., GohC.L.The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol.2000; 143: 969–73.
27.
GuptaM.A., GuptaA.K., SchorkN.J., EllisC.N.Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med.1994; 56: 36–40.
28.
GuptaM.A., GuptaA.K., KirkbyS.Pruritus in psoriasis: a prospective study of some psychiatric and dermatologic correlates. Arch Dermatol.1988; 124: 1052–7.
29.
GuptaM.A., GuptaA.K., KirkbyS.Pruritus associated with nocturnal wakenings: organic or psychogenic?J Am Acad Dermatol.1989; 21: 479–84.
30.
BuslauM., BenotmaneK.Cardiovascular complications of psoriasis: does obstructive sleep apnoea play a role?Acta Derm Venereol.1999; 79: 234.
31.
WuY., MillsD., BalaM.Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol.2008; 7: 373–7.
32.
ChristensenT.E., CallisK.P., PapenfussJ.Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypes. J Invest Dermatol.2006; 126: 2397–403.
33.
BuysseD.J., ReynoldsCF3rd, MonkT.H., BermanS.R., KupferD.J.The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res.1989; 28: 193–213.
34.
SchwartzA.L., MeekP.M., NailL.M.Measurement of fatigue. determining minimally important clinical differences. J Clin Epidemiol.2002; 55: 239–44.
35.
Drossaers-BakkerK.W., HamburgerH.L., BongartzE.B., DijkmansB.A., Van SoesbergenR.M.Sleep apnoea caused by rheumatoid arthritis. Br J Rheumatol.1998; 37: 889–94.
36.
GudbjornssonB., BromanJ.E., HettaJ., HallgrenR.Sleep disturbances in patients with primary Sjogren's syndrome. Br J Rheumatol.1993; 32: 1072–6.
37.
HirschM., CarlanderB., VergeM.Objective and subjective sleep disturbances in patients with rheumatoid arthritis: a reappraisal. Arthritis Rheum.1994; 37: 41–9.
38.
LavieP., NahirM., LorberM., ScharfY.Nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis patients: lack of association between clinical improvement and effects on sleep. Arthritis Rheum.1991; 34: 655–9.
Redlund-JohnellI.Upper airway obstruction in patients with rheumatoid arthritis and temporomandibular joint destruction. Scand J Rheumatol.1988; 17: 273–9.
41.
AbadV.C., SarinasP.S., GuilleminaultC.Sleep and rheumatologic disorders. Sleep Med Rev.2008; 12: 211–28.
42.
WardM.M.Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res.1999; 12: 247–55.
43.
SolakO., FidanF., DundarU.The prevalence of obstructive sleep apnoea syndrome in ankylosing spondylitis patients. Rheumatology (Oxf).2009; 48: 433–5.
44.
ErbN., KarokisD., DelamereJ.P., CushleyM.J., KitasG.D.Obstructive sleep apnoea as a cause of fatigue in ankylosing spondylitis. Ann Rheum Dis.2003; 62: 183–4.
45.
WinkelmanJ.W., FinnL., YoungT.Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med.2006; 7: 545–52.
46.
TamL.S., TomlinsonB., ChuT.T.Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology (Oxf).2008; 47: 718–23.
47.
ChandranV., BhellaS., SchentagC., GladmanD.D.Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis.2007; 66: 936–9.
48.
YosipovitchG., FleischerA.Itch associated with skin disease: advances in pathophysiology and emerging therapies. Am J Clin Dermatol.2003; 4: 617–22.
49.
GladmanD.D., AngM., SuL., TomB.D., SchentagC.T., FarewellV.T.Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis.2009; 68: 1131–5.
